DK3744319T3 - Stabil lyofiliseret formulering til hybrid fc-fusioneret g-csf - Google Patents

Stabil lyofiliseret formulering til hybrid fc-fusioneret g-csf Download PDF

Info

Publication number
DK3744319T3
DK3744319T3 DK19177024.7T DK19177024T DK3744319T3 DK 3744319 T3 DK3744319 T3 DK 3744319T3 DK 19177024 T DK19177024 T DK 19177024T DK 3744319 T3 DK3744319 T3 DK 3744319T3
Authority
DK
Denmark
Prior art keywords
fusioned
csf
hybrid
lyophilized formulation
stable lyophilized
Prior art date
Application number
DK19177024.7T
Other languages
English (en)
Inventor
Hatice Öncel
Emine Duygu Daglikoca
Adem Sahin
Pala Meltem Çorbacioglu
Aylin Özkan
Onur Pinarbasli
Nagehan Sarracoglu
Original Assignee
Ilkogen Ilac Sanayi Ve Ticaret A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ilkogen Ilac Sanayi Ve Ticaret A S filed Critical Ilkogen Ilac Sanayi Ve Ticaret A S
Application granted granted Critical
Publication of DK3744319T3 publication Critical patent/DK3744319T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
DK19177024.7T 2019-05-28 2019-05-28 Stabil lyofiliseret formulering til hybrid fc-fusioneret g-csf DK3744319T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19177024.7A EP3744319B1 (en) 2019-05-28 2019-05-28 A stable lyophilized formulation for hybrid fc fused g-csf

Publications (1)

Publication Number Publication Date
DK3744319T3 true DK3744319T3 (da) 2023-01-16

Family

ID=66668847

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19177024.7T DK3744319T3 (da) 2019-05-28 2019-05-28 Stabil lyofiliseret formulering til hybrid fc-fusioneret g-csf

Country Status (6)

Country Link
US (1) US20220288167A1 (da)
EP (1) EP3744319B1 (da)
KR (1) KR20220080046A (da)
DK (1) DK3744319T3 (da)
EA (1) EA202193289A1 (da)
WO (1) WO2020242419A1 (da)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4242863A1 (de) 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
EP3173484B1 (en) * 2007-05-30 2018-09-26 Postech Academy-Industry- Foundation Immunoglobulin fusion proteins
WO2011090305A2 (en) * 2010-01-19 2011-07-28 Hanmi Holdings Co., Ltd Liquid formulations for long-acting g-csf conjugate
EP2945593A4 (en) 2013-01-15 2016-08-31 Teva Pharma METHOD OF LYOPHILIZATION
US10918698B2 (en) * 2014-03-29 2021-02-16 Intas Pharmaceuticals Ltd. Lyophilized pharmaceutical composition of Fc-peptide fusion protein
KR102605317B1 (ko) * 2016-10-07 2023-11-24 리제너론 파아마슈티컬스, 인크. 실온 안정성 동결건조된 단백질

Also Published As

Publication number Publication date
EA202193289A1 (ru) 2022-02-22
KR20220080046A (ko) 2022-06-14
EP3744319B1 (en) 2022-10-19
EP3744319A1 (en) 2020-12-02
WO2020242419A1 (en) 2020-12-03
US20220288167A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
MA54714A (fr) Formulation de nicotine
EP3890732A4 (en) INJECTABLE FORMULATIONS
DK3337502T3 (da) Stabil anti-ifnar1-formulering
EP3432870A4 (en) COMPOSITIONS WITH CHOLIN
EP3265098A4 (en) COMPOSITIONS FOR MODULATING MECP2 EXPRESSION
IL282617A (en) Aerosol formulation
GB201801614D0 (en) Formulation
IL282523A (en) Aerosol formulation
IL282589A (en) Aerosol formulation
GB201816447D0 (en) Formulation
EP3262522A4 (en) Private application platform
EP3530729A4 (en) LIQUID FOR PRESERVING LIVING CELLS OR COMPOSITION CONTAINING LIVING CELLS
IL282461A (en) Aerosol formulation
IL282392A (en) Aerosol formulation
EP3122352A4 (en) Stable veterinary anthelmintic formulations
IL282697A (en) Aerosol formulation
EP3682016A4 (en) FORMULATIONS FOR ADMINISTERING COMPOUNDS
EP3689333A4 (en) LOCAL INJECTION SOLUTION WITH TWO MEDICINAL PRODUCTS FOR SUBMUCOSAL INJECTION
EP3600279A4 (en) 1-AMINO-1-CYCLOPROPANCARBONIC ACID FORMULATIONS
EP3527077A4 (en) PRESERVATION SOLUTION FOR LIVING CELLS OR COMPOSITION WITH LIVING CELLS
EP3866783A4 (en) INTRATUMOR INJECTION FORMULATION
EP3355894A4 (en) COMPOSITION FOR MAINTAINING LACTOBACILLUS DOMINANCE
EP3894434A4 (en) ERYTHROPOIETIN ANALOGS FOR VETERINARY USE
GB201902551D0 (en) Formulation
DK3744319T3 (da) Stabil lyofiliseret formulering til hybrid fc-fusioneret g-csf